Catalog Advanced Search
Leon Schiff State-of-the-Art LectureContains 2 Component(s) Recorded On: 11/13/2018
AASLD's Leon Schiff State-of-the-Art Lecture presented at The Liver Meeting® 2018.
This lecture summarizes the current approach to understanding NASH pathogenesis, and how to translate recent advances into routine clinical care. Beginning with an overview of key pathogenic steps in development and progression of NASH, the program will also cover different therapeutic approaches for specific subsets of patients with NASH and related complications, and risk stratification of patients with respect to clinical outcomes.
Michael W. Fried (Moderator)
Arun J. Sanyal
2018 NAFLD DebriefContains 2 Component(s) Recorded On: 11/13/2018
AASLD's NAFLD Debrief presented at The Liver Meeting® 2018.
This session is designed to complement the highly-regarded, Hepatitis and Clinical Hepatology Debriefs, and will review key highlights from The Liver Meeting®.
Jorge A. Bezerra (Moderator)
Mary E. McCarthy Rinella
Hyman J. Zimmerman Hepatotoxicity State-of-the-Art LectureContains 2 Component(s) Recorded On: 11/12/2018
AASLD's Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture presented at The Liver Meeting® 2018.
Patients with underlying chronic liver disease (CLD) may develop drug-induced liver injury during clinical care or in clinical trials, and it is associated with poor outcomes. This lecture discusses medications and herbal agents that are commonly implicated in DILI, risk factors, strategies for monitoring patients in clinical trials, guidelines for adjudicating suspected DILI events and outcomes associated with DILI in CLD.
Raymond T. Chung (Moderator)
Naga P. Chalasani
2018 Advances for PractitionersContains 5 Component(s) Recorded On: 11/12/2018
AASLD's Advances for Practitioners presented at The Liver Meeting® 2018.
This program reviews the most recent advances in the clinical management of patients with cirrhosis. Topics of discussion include the use of beta blockers, anticoagulants and albumin for managing different complications of cirrhosis. Additionally, the most updated recommendations regarding screening issues for patients with cirrhosis will be reviewed.
Michael B. Fallon
Juan G. Abraldes
Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.
Nicolas M. Intagliata
Clinical Practice SIG: Best Practices in Hepatology 2018Contains 8 Component(s) Recorded On: 11/12/2018
AASLD's Clinical Practice SIG presented at The Liver Meeting® 2018.
This program aims to help attendees understand how to best approach the patient referred for evaluation of an incidentally found liver mass, be better informed on how to conduct office-based noninvasive assessment of liver fibrosis in the patient with elevated liver tests, increase their understanding of the management of alcoholic liver disease in 2018 and have the knowledge to provide care in the post-liver transplant patient in the community setting.
K. Rajender Reddy
Craig J. McClain
Diversity Workshop: Ethnic and Racial Disparities in Liver DiseasesContains 7 Component(s) Recorded On: 11/12/2018
AASLD's Diversity Workshop presented at The Liver Meeting® 2018.
This session will describe the biological and social determinants of health that contribute to ethnic and racial disparities in health and health care; identify the racial and ethnic disparities that have been documented in patients with primary HCC and liver transplantation; and list strategies to prevent viral hepatitis, reduce deaths and decrease health disparities due to HBV and HCV in the U.S.
Kimberly A. Forde
Andrew J. Muir
Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. Through his work at the Durham Veterans Administration Medical Center, Dr. Muir has participated in the development programs of many of the direct acting antiviral agents that have revolutionized hepatitis C care. He assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010 and has expanded the research portfolio to include other liver disorders and gastroenterology outcomes. His particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.
2018 Global Forum: Global Challenges in HCC Risk and SurveillanceContains 8 Component(s) Recorded On: 11/12/2018
AASLD's Global Forum presented at The Liver Meeting® 2018.
HCC is the fifth most common cancer and the third cause of cancer-related deaths worldwide. The underlying liver disease that ultimately leads to HCC varies throughout the world. Identifying the population at risk for HCC is critical in order to implement preventive strategies to reduce the burden of the disease. Moreover, identifying the population at risk will facilitate the use of surveillance programs. This forum will review, in all pertinent regions of the world, the main populations at risk for HCC and discuss strategies for reducing the burden of the disease through prevention and surveillance.
Hashem B. El-Serag
Diana A. Payawal
Flair Jose Carrilho
AASLD/ALEH Joint SymposiumContains 8 Component(s) Recorded On: 11/11/2018
AASLD/ALEH Joint Symposium presented at The Liver Meeting® 2018.
The goal of this program is to highlight the hepatic manifestations of various diseases endemic or epidemic in the Tropics. These diseases include viral A and E hepatitis; hepatic manifestations of viral epidemics like Dengue, SARS, and Zika virus; bacterial infections like typhoid; and parasitic diseases like malaria.
Maria Cassia Mendes
General Hepatology UpdateContains 5 Component(s) Recorded On: 11/11/2018
AASLD's General Hepatology Update presented at The Liver Meeting® 2018.
This activity will provide updates and practical guidance for care providers dealing with 3 common and or difficult to manage conditions. The knowledge will improve practitioner's performance as care providers and will improve patient outcomes.
Mina Rakoski is a Transplant Hepatologist at Loma Linda University Health. She completed her medical education at Jefferson Medical College in Philadelphia, her residency at Cedars-Sinai Medical Center in Los Angeles and her Gastroenterology and Transplant Hepatology Fellowships at University of Michigan in Ann Arbor. During her time at University of Michigan, she attained her Master of Science in Health and Health Care Research through the Rackham Graduate School.
Dr. Rakoski has a clinical and research interest in palliative care for patients with cirrhosis and hepatocellular carcinoma. She has a dual appointment in both Gastroenterology as well as Palliative Care at Loma Linda. She has started a hepatology palliative care clinic where she is able to provide integrated hepatology and palliative care services including in-office therapeutic paracentesis for patients with advanced liver disease. She is a co-investigator on a multicenter study funded by Patient-Centered Outcomes Research Institute (PCORI), which is investigating a novel approach of integrating palliative care into subspecialty clinics. She has written several review articles on palliative care in liver disease as well as presented on this topic at national conferences.
Hepatitis B SIG: HBV Flares: Distinguishing the Good from the BadContains 10 Component(s) Recorded On: 11/11/2018
AASLD'S Hepatitis B SIG: HBV Flares: Distinguishing the Good from the Bad presented at The Liver Meeting® 2018.
Chronic HBV (CHB) infection follows a dynamic course with multiple phases of disease with various durations. ALT flares during CHB can be challenging for clinicians to manage. In some settings ALT flares herald a transition from active to inactive disease and thus are considered to be beneficial. In other scenarios, they may indicate aggressive inflammatory liver disease than can lead to progressive liver injury or even fulminant hepatic failure. Understanding and distinguishing these 'good' and 'bad' flares is not only a clinical challenge but a key to understanding the natural history and the therapeutic goals of HBV treatment. The program starts with a definition of flares and the current understanding of their immunological pathophysiology. Flares in different clinical settings will also be discussed (focusing on their beneficial and potentially harmful effects). Finally, attendees will hear about management strategies for ATL flares.
Marc G. Ghany
Dr. Ghany is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis.
Dr. Kyong-Mi Chang is an Associate Professor of Medicine in the Division of Gastroenterology at the University of Pennsylvania Perelman School of Medicine, with administrative leadership role as the Associate Chief of Staff and Associate Dean for Research at the Philadelphia Corporal Michael J. Crescenz VA Medical Center (CMC VAMC). Dr. Chang received her MD and Internal Medicine residency training from the Medical College of Pennsylvania, followed by clinical GI fellowship training at the University of California in San Diego, also receiving her postdoctoral research training at the Scripps Research Institute studying CTL escape in HCV persistence. She has been a faculty member in GI Division at the University of Pennsylvania School of Medicine and the CMC VAMC since 1999 with active clinical and research activities. Her translational research focuses on immune pathogenesis in human hepatitis C and B virus infection with and without HIV coinfection—including various immune regulatory mechanisms such as FoxP3+ Tregs, IL-10+ Tr1 cells, gdT-cells, PD-1 and CTLA-4. Dr. Chang is also participating in the Million Veteran Program—a multi-center VA genomic study. She is a Fellow of the American Association for Study of Liver Disease (FAASLD) and a member of the American Society for Clinical Investigation (ASCI).
Anna S. Lok